ChemoMetec A/S

CPSE:CHEMM Stock Report

Market Cap: DKK 8.4b

ChemoMetec Valuation

Is CHEMM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHEMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHEMM (DKK483) is trading above our estimate of fair value (DKK333.91)

Significantly Below Fair Value: CHEMM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHEMM?

Key metric: As CHEMM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHEMM. This is calculated by dividing CHEMM's market cap by their current earnings.
What is CHEMM's PE Ratio?
PE Ratio61.7x
EarningsDKK 136.28m
Market CapDKK 8.41b

Price to Earnings Ratio vs Peers

How does CHEMM's PE Ratio compare to its peers?

The above table shows the PE ratio for CHEMM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.7x
ALK B ALK-Abelló
45.5x21.5%DKK 35.7b
HLUN B H. Lundbeck
15.2x8.8%DKK 39.2b
BAVA Bavarian Nordic
14x3.6%DKK 15.6b
AKUMS Akums Drugs and Pharmaceuticals
32.3xn/a₹89.8b
CHEMM ChemoMetec
61.7x17.2%DKK 8.4b

Price-To-Earnings vs Peers: CHEMM is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the peer average (26.7x).

Price to Earnings Ratio vs Industry

How does CHEMM's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
CHEMM 61.7xIndustry Avg. 38.6xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHEMM is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the European Life Sciences industry average (38.6x).

Price to Earnings Ratio vs Fair Ratio

What is CHEMM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHEMM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.7x
Fair PE Ratio25x

Price-To-Earnings vs Fair Ratio: CHEMM is expensive based on its Price-To-Earnings Ratio (61.7x) compared to the estimated Fair Price-To-Earnings Ratio (25x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHEMM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 483.00
DKK 545.00
+12.8%
0.9%DKK 550.00DKK 540.00n/a2
Dec ’25DKK 473.60
DKK 545.00
+15.1%
0.9%DKK 550.00DKK 540.00n/a2
Nov ’25DKK 408.00
DKK 438.33
+7.4%
16.2%DKK 505.00DKK 340.00n/a3
Oct ’25DKK 397.60
DKK 436.67
+9.8%
16.8%DKK 505.00DKK 335.00n/a3
Sep ’25DKK 374.60
DKK 462.50
+23.5%
2.7%DKK 475.00DKK 450.00n/a2
Aug ’25DKK 377.40
DKK 437.50
+15.9%
8.6%DKK 475.00DKK 400.00n/a2
Jul ’25DKK 301.40
DKK 437.50
+45.2%
8.6%DKK 475.00DKK 400.00n/a2
Jun ’25DKK 363.20
DKK 437.50
+20.5%
8.6%DKK 475.00DKK 400.00n/a2
May ’25DKK 294.80
DKK 462.50
+56.9%
13.5%DKK 525.00DKK 400.00n/a2
Apr ’25DKK 423.80
DKK 451.67
+6.6%
19.2%DKK 525.00DKK 330.00n/a3
Mar ’25DKK 507.00
DKK 451.67
-10.9%
19.2%DKK 525.00DKK 330.00n/a3
Feb ’25DKK 363.60
DKK 448.33
+23.3%
20.4%DKK 525.00DKK 320.00n/a3

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 23:40
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kallum TitchmarshBofA Global Research
null nullDanske Bank
Simon LarssonDanske Bank